Literature DB >> 25801706

Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1.

Adrian Israelson1, Dara Ditsworth2, Shuying Sun2, SungWon Song3, Jason Liang4, Marian Hruska-Plochan5, Melissa McAlonis-Downes4, Salah Abu-Hamad6, Guy Zoltsman6, Tom Shani6, Marcus Maldonado4, Anh Bui4, Michael Navarro5, Huilin Zhou2, Martin Marsala5, Brian K Kaspar7, Sandrine Da Cruz4, Don W Cleveland8.   

Abstract

Mutations in superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by loss of motor neurons and accompanied by accumulation of misfolded SOD1 onto the cytoplasmic faces of intracellular organelles, including mitochondria and the endoplasmic reticulum (ER). Using inhibition of misfolded SOD1 deposition onto mitochondria as an assay, a chaperone activity abundant in nonneuronal tissues is now purified and identified to be the multifunctional macrophage migration inhibitory factor (MIF), whose activities include an ATP-independent protein folding chaperone. Purified MIF is shown to directly inhibit mutant SOD1 misfolding. Elevating MIF in neuronal cells suppresses accumulation of misfolded SOD1 and its association with mitochondria and the ER and extends survival of mutant SOD1-expressing motor neurons. Accumulated MIF protein is identified to be low in motor neurons, implicating correspondingly low chaperone activity as a component of vulnerability to mutant SOD1 misfolding and supporting therapies to enhance intracellular MIF chaperone activity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801706      PMCID: PMC4393372          DOI: 10.1016/j.neuron.2015.02.034

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  79 in total

1.  Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS.

Authors:  Francois Gros-Louis; Geneviève Soucy; Roxanne Larivière; Jean-Pierre Julien
Journal:  J Neurochem       Date:  2010-03-14       Impact factor: 5.372

2.  The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis.

Authors:  Mai Tuyet Nguyen; Hongqi Lue; Robert Kleemann; Michael Thiele; Gabriele Tolle; Doris Finkelmeier; Eva Wagner; Andrea Braun; Jürgen Bernhagen
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

3.  ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2.

Authors:  Steve Pedrini; Daniela Sau; Stefania Guareschi; Marina Bogush; Robert H Brown; Nicole Naniche; Azadeh Kia; Davide Trotti; Piera Pasinelli
Journal:  Hum Mol Genet       Date:  2010-05-11       Impact factor: 6.150

4.  The atheroprotective properties of Hsp70: a role for Hsp70-endothelial interactions?

Authors:  A Graham Pockley; Stuart K Calderwood; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2009-04-09       Impact factor: 3.667

5.  The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor.

Authors:  Melanie Merk; John Baugh; Swen Zierow; Lin Leng; Utpal Pal; Seung Joon Lee; Antje D Ebert; Yuka Mizue; John O Trent; Robert Mitchell; Walter Nickel; Paula B Kavathas; Jürgen Bernhagen; Richard Bucala
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

6.  Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice.

Authors:  Marina Mattiazzi; Marilena D'Aurelio; Carl D Gajewski; Katherine Martushova; Mahmoud Kiaei; M Flint Beal; Giovanni Manfredi
Journal:  J Biol Chem       Date:  2002-06-05       Impact factor: 5.157

7.  An examination of alpha B-crystallin as a modifier of SOD1 aggregate pathology and toxicity in models of familial amyotrophic lateral sclerosis.

Authors:  Celeste M Karch; David R Borchelt
Journal:  J Neurochem       Date:  2010-01-07       Impact factor: 5.372

8.  Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis.

Authors:  Hsueh-Ning Liu; Teresa Sanelli; Patrick Horne; Erik P Pioro; Michael J Strong; Ekaterina Rogaeva; Juan Bilbao; Lorne Zinman; Janice Robertson
Journal:  Ann Neurol       Date:  2009-07       Impact factor: 10.422

9.  Two factor reprogramming of human neural stem cells into pluripotency.

Authors:  Mark E Hester; Sungwon Song; Carlos J Miranda; Amy Eagle; Phillip H Schwartz; Brian K Kaspar
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

Review 10.  Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond.

Authors:  Hristelina Ilieva; Magdalini Polymenidou; Don W Cleveland
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more
  43 in total

Review 1.  Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.

Authors:  Ying Liu; Wenbin Deng
Journal:  Brain Res       Date:  2015-09-28       Impact factor: 3.252

2.  AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.

Authors:  Marcel F Leyton-Jaimes; Joy Kahn; Adrian Israelson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-01       Impact factor: 11.205

3.  Misfolded SOD1 is not a primary component of sporadic ALS.

Authors:  Sandrine Da Cruz; Anh Bui; Shahram Saberi; Sandra K Lee; Jennifer Stauffer; Melissa McAlonis-Downes; Derek Schulte; Donald P Pizzo; Philippe A Parone; Don W Cleveland; John Ravits
Journal:  Acta Neuropathol       Date:  2017-02-28       Impact factor: 17.088

4.  Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; William L Jorgensen
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

5.  Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS.

Authors:  Shuying Sun; Ying Sun; Shuo-Chien Ling; Laura Ferraiuolo; Melissa McAlonis-Downes; Yiyang Zou; Kevin Drenner; Yin Wang; Dara Ditsworth; Seiya Tokunaga; Alex Kopelevich; Brian K Kaspar; Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

6.  Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS.

Authors:  Marcel F Leyton-Jaimes; Clara Benaim; Salah Abu-Hamad; Joy Kahn; Amos Guetta; Richard Bucala; Adrian Israelson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-22       Impact factor: 11.205

7.  MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.

Authors:  Qiang Wang; Dongyu Zhao; Miao Xian; Zhuo Wang; Enguang Bi; Pan Su; Jianfei Qian; Xingzhe Ma; Maojie Yang; Lintao Liu; Youli Zu; Sai Ravi Pingali; Kaifu Chen; Zhen Cai; Qing Yi
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

8.  HSPB1 mutations causing hereditary neuropathy in humans disrupt non-cell autonomous protection of motor neurons.

Authors:  Patrick L Heilman; SungWon Song; Carlos J Miranda; Kathrin Meyer; Amit K Srivastava; Amy Knapp; Christopher G Wier; Brian K Kaspar; Stephen J Kolb
Journal:  Exp Neurol       Date:  2017-08-07       Impact factor: 5.330

9.  Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients.

Authors:  Larry Lam; Lydia Chin; Ramesh C Halder; Bien Sagong; Sam Famenini; James Sayre; Dennis Montoya; Liudmilla Rubbi; Matteo Pellegrini; Milan Fiala
Journal:  FASEB J       Date:  2016-07-01       Impact factor: 5.191

10.  A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity.

Authors:  Victor Banerjee; Ofek Oren; Efrat Ben-Zeev; Ran Taube; Stanislav Engel; Niv Papo
Journal:  J Biol Chem       Date:  2017-08-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.